Recent News

• 11.03.2026 - Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
• 11.03.2026 - Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
• 10.28.2026 - Axogen, Inc. Reports Third Quarter 2026 Financial Results
• 10.28.2026 - Axogen, Inc. Reports Third Quarter 2026 Financial Results
• 10.28.2026 - Corporate Presentation
• 10.28.2026 - Q3 2026 Financial Results Presentation
• 10.14.2026 - Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
• 10.14.2026 - Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
• 10.01.2026 - Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
• 10.01.2026 - Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

Recent Filings

• 10.28.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.28.2026 - 8-K Current report
• 10.28.2026 - EX-99.1 EX-99.1
• 10.02.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.01.2026 - 8-K Current report
• 10.01.2026 - EX-99.1 EX-99.1
• 09.10.2026 - 8-K/A Current report
• 09.10.2026 - 8-K Current report
• 09.10.2026 - EX-99.1 EX-99.1
• 09.10.2026 - 424B5 Prospectus [Rule 424(b)(5)]